Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Tetsuhiro Yoshinami"'
Autor:
Masato Takahashi, Yuichiro Kikawa, Kosuke Kashiwabara, Naruto Taira, Tsuguo Iwatani, Kojiro Shimozuma, Shoichiro Ohtani, Tetsuhiro Yoshinami, Junichiro Watanabe, Masahiro Kashiwaba, Ken-ichi Watanabe, Masahiro Kitada, Koichi Sakaguchi, Yuko Tanabe, Tomohiko Aihara, Hirofumi Mukai
Publikováno v:
EClinicalMedicine, Vol 74, Iss , Pp 102715- (2024)
Summary: Background: Eribulin prolongs overall survival (OS) of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), particularly in later chemotherapy (ChT) treatment. However, the health-related qua
Externí odkaz:
https://doaj.org/article/1723e209a4034dd0b0e8a27d67cd3241
Autor:
Tomonori Tanei, Shigeto Seno, Yoshiaki Sota, Takaaki Hatano, Yuri Kitahara, Kaori Abe, Nanae Masunaga, Masami Tsukabe, Tetsuhiro Yoshinami, Tomohiro Miyake, Masafumi Shimoda, Hideo Matsuda, Kenzo Shimazu
Publikováno v:
Cancers, Vol 16, Iss 5, p 1062 (2024)
Purpose: Breast cancer tumors frequently have intratumoral heterogeneity (ITH). Tumors with high ITH cause therapeutic resistance and have human epidermal growth factor receptor 2 (HER2) heterogeneity in response to HER2-targeted therapies. This stud
Externí odkaz:
https://doaj.org/article/d1921906ca1f419bbdf0aefc7a03bb99
Autor:
Sakina Hashizume, Masafumi Shimoda, Tetsuhiro Yoshinami, Kaori Abe, Nanae Masunaga, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Kenzo Shimazu
Publikováno v:
Surgical Case Reports, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Background Since humoral hypercalcemia of malignancy (HHM) in breast cancer patients without bone metastasis is rare, the clinical features of this condition are not fully understood. Case presentation During the recent 12 years, 3602 patien
Externí odkaz:
https://doaj.org/article/99f8a25b55544e639cc9a37f0bfcc515
Autor:
Kaori Abe, Masafumi Shimoda, Tetsuhiro Yoshinami, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Naofumi Kagara, Yasuto Naoi, Kenzo Shimazu
Publikováno v:
Surgical Case Reports, Vol 8, Iss 1, Pp 1-4 (2022)
Abstract Background Everolimus is a mechanistic-target-of-rapamycin (mTOR) inhibitor bearing a potent antitumor effect against hormone receptor-positive breast cancer. Here, we report the case of a patient with recurrent breast cancer who developed o
Externí odkaz:
https://doaj.org/article/eba388cc49fd4a3d90db9f002a36da61
Autor:
Yoko Hashimoto, Nanae Masunaga, Naofumi Kagara, Kaori Abe, Tetsuhiro Yoshinami, Masami Tsukabe, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Masafumi Shimoda, Kenzo Shimazu
Publikováno v:
Cancers, Vol 15, Iss 9, p 2632 (2023)
ESR1 mutations in breast cancer are one of the mechanisms of resistance to aromatase inhibitors. These mutations are common in metastatic breast cancer; however, these are rare in primary breast cancer. However, these data have been analyzed mainly i
Externí odkaz:
https://doaj.org/article/9c6bd46c1bf144e18e12e0c79771ec89
Autor:
Takahiro Nakayama, Tetsuhiro Yoshinami, Hiroyuki Yasojima, Nobuyoshi Kittaka, Masato Takahashi, Shoichiro Ohtani, Seung Jin Kim, Hiroyuki Kurakami, Naoko Yamamoto, Tomomi Yamada, Takehiko Takata, Norikazu Masuda
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Trastuzumab emtansine (T-DM1) is a second-line standard therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Evidence regarding post–T-DM1 treatments is currently lacking.
Externí odkaz:
https://doaj.org/article/8b02d3fbc4a34996b43ef5c3f608feda
Autor:
Tsutomu Iwasa, Junji Tsurutani, Satomi Watanabe, Ryoji Kato, Yutaka Mizuno, Yasuyuki Kojima, Tsutomu Takashima, Nobuki Matsunami, Takashi Morimoto, Jun Yamamura, Shoichiro Ohtani, Yuko Tanabe, Tetsuhiro Yoshinami, Toshimi Takano, Yoshifumi Komoike, Kazuhiko Nakagawa
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background We previously reported the synergistic effect of S-1 and eribulin in preclinical models. In addition, our phase I study revealed the recommended dose for the phase II study of the combination therapy in advanced breast cancer (ABC
Externí odkaz:
https://doaj.org/article/0a03588daea444e08474b844baa4c3b0
Autor:
Tetsuhiro Yoshinami, Naofumi Kagara, Daisuke Motooka, Shota Nakamura, Tomohiro Miyake, Tomonori Tanei, Yasuto Naoi, Masafumi Shimoda, Kenzo Shimazu, Seung Jin Kim, Shinzaburo Noguchi
Publikováno v:
Translational Oncology, Vol 13, Iss 8, Pp 100787- (2020)
We attempted to detect circulating tumor DNA (ctDNA), taking advantage of molecular barcode next-generation sequencing (MB-NGS), which can be more easily customized to detect a variety of mutations with a high sensitivity than PCR-based methods. Sequ
Externí odkaz:
https://doaj.org/article/dddc80bc73bf49589624688a637e2652
Autor:
Norikazu Masuda, Tetsuhiro Yoshinami, Masahiko Ikeda, Makiko Mizutani, Miki Yamaguchi, Yoshifumi Komoike, Tsutomu Takashima, Katsuhide Yoshidome, Junji Tsurutani, Mitsuhiko Iwamoto, Fumie Fujisawa, Hiroyuki Yasojima, Jun Yamamura, Hirotaka Morishima, Fuminori Aki, Tomomi Yamada, Satoshi Morita, Takahiro Nakayama
Publikováno v:
Cancers, Vol 13, Iss 17, p 4399 (2021)
Optimal treatment strategies for hormone receptor (HR)-positive, HER2-negative advanced and/or metastatic breast cancer (AMBC) remain uncertain. We investigated the clinical usefulness of adding capecitabine to maintenance endocrine therapy after ind
Externí odkaz:
https://doaj.org/article/b43fa8e974b1476bbe4d4c08d0d15a59
Autor:
SUNG AE PARK, NANAE MASUNAGA, NAOFUMI KAGARA, YASUYO OHI, NAOMI GONDO, KAORI ABE, TETSUHIRO YOSHINAMI, YOSHIAKI SOTA, TOMOHIRO MIYAKE, TOMONORI TANEI, MASAFUMI SHIMODA, YASUAKI SAGARA, KENZO SHIMAZU
Publikováno v:
Oncology Letters; Nov2023, Vol. 26 Issue 5, p1-7, 7p